image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - CA
$ 7.305
-1.81 %
$ 2.69 B
Market Cap
-56.19
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one BHC stock under the worst case scenario is HIDDEN Compared to the current market price of 7.3 USD, Bausch Health Companies Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one BHC stock under the base case scenario is HIDDEN Compared to the current market price of 7.3 USD, Bausch Health Companies Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one BHC stock under the best case scenario is HIDDEN Compared to the current market price of 7.3 USD, Bausch Health Companies Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
9.52 B REVENUE
8.69%
1.55 B OPERATING INCOME
60.54%
-72 M NET INCOME
88.22%
1.6 B OPERATING CASH FLOW
54.75%
-454 M INVESTING CASH FLOW
78.83%
-868 M FINANCING CASH FLOW
-58.85%
2.51 B REVENUE
4.47%
318 M OPERATING INCOME
-25.34%
-92 M NET INCOME
-920.19%
411 M OPERATING CASH FLOW
8.56%
-102 M INVESTING CASH FLOW
-29.18%
-189 M FINANCING CASH FLOW
55.36%
Balance Sheet Bausch Health Companies Inc.
image
Current Assets 5.77 B
Cash & Short-Term Investments 1.18 B
Receivables 2.14 B
Other Current Assets 2.45 B
Non-Current Assets 20.7 B
Long-Term Investments 0
PP&E 1.78 B
Other Non-Current Assets 19 B
Current Liabilities 6.75 B
Accounts Payable 656 M
Short-Term Debt 2.67 B
Other Current Liabilities 3.42 B
Non-Current Liabilities 20.1 B
Long-Term Debt 0
Other Non-Current Liabilities 20.1 B
EFFICIENCY
Earnings Waterfall Bausch Health Companies Inc.
image
Revenue 9.52 B
Cost Of Revenue 53 M
Gross Profit 9.46 B
Operating Expenses 3.91 B
Operating Income 1.55 B
Other Expenses 1.62 B
Net Income -72 M
RATIOS
99.44% GROSS MARGIN
99.44%
16.24% OPERATING MARGIN
16.24%
4.27% NET MARGIN
4.27%
-31.74% ROE
-31.74%
1.53% ROA
1.53%
16.75% ROIC
16.75%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bausch Health Companies Inc.
image
Net Income -72 M
Depreciation & Amortization 1.27 B
Capital Expenditures -337 M
Stock-Based Compensation 150 M
Change in Working Capital 0
Others 186 M
Free Cash Flow 1.26 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bausch Health Companies Inc.
image
Wall Street analysts predict an average 1-year price target for BHC of $10.4 , with forecasts ranging from a low of $7 to a high of $16 .
BHC Lowest Price Target Wall Street Target
7 USD -4.18%
BHC Average Price Target Wall Street Target
10.4 USD 42.76%
BHC Highest Price Target Wall Street Target
16 USD 119.03%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Bausch Health Companies Inc.
image
Sold
0-3 MONTHS
3.67 K USD 1
3-6 MONTHS
83 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
61.9 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 months ago
Dec 02, 2024
Sell 3.67 K USD
Carson Seana
EVP, General Counsel
- 440
8.35 USD
5 months ago
Sep 06, 2024
Sell 83 K USD
Carson Seana
EVP, General Counsel
- 13370
6.21 USD
1 year ago
Mar 04, 2024
Sell 43.3 K USD
Carson Seana
EVP, General Counsel
- 4420
9.8 USD
1 year ago
Mar 04, 2024
Sell 1.95 K USD
Carson Seana
EVP, General Counsel
- 199
9.8 USD
1 year ago
Mar 04, 2024
Sell 15.3 K USD
Carson Seana
EVP, General Counsel
- 1561
9.8 USD
1 year ago
Mar 04, 2024
Sell 1.3 K USD
Carson Seana
EVP, General Counsel
- 133
9.8 USD
1 year ago
Dec 05, 2023
Sell 1.62 K USD
Carson Seana
EVP, General Counsel
- 220
7.38 USD
1 year ago
Nov 06, 2023
Sell 327 USD
Carson Seana
EVP, General Counsel
- 43
7.61 USD
1 year ago
Sep 06, 2023
Sell 55.4 K USD
Carson Seana
EVP, General Counsel
- 6685
8.28 USD
2 years ago
Mar 03, 2023
Sell 7.29 K USD
Carson Seana
EVP, General Counsel
- 780
9.34 USD
1 year ago
Mar 06, 2023
Sell 4.54 K USD
Carson Seana
EVP, General Counsel
- 495
9.17 USD
2 years ago
Feb 28, 2023
Sell 2.72 K USD
Carson Seana
EVP, General Counsel
- 292
9.32 USD
2 years ago
Apr 14, 2022
Sell 35.4 K USD
Spurr Robert
U.S. President-Pharma Business
- 1595
22.19 USD
2 years ago
Mar 15, 2022
Sell 108 K USD
Spurr Robert
U.S. President-Pharma Business
- 4846
22.2 USD
2 years ago
Mar 08, 2022
Sell 84.6 K USD
Gordon Joseph F
Pres&Co-Head Bausch&Lomb/Int'l
- 3889
21.76 USD
3 years ago
Mar 02, 2022
Sell 259 K USD
Gordon Joseph F
Pres&Co-Head Bausch&Lomb/Int'l
- 11077
23.37 USD
3 years ago
Mar 02, 2022
Sell 37.3 K USD
Spurr Robert
U.S. President-Pharma Business
- 1595
23.37 USD
3 years ago
Mar 01, 2022
Sell 151 K USD
Gordon Joseph F
Pres&Co-Head Bausch&Lomb/Int'l
- 6338
23.82 USD
3 years ago
Feb 15, 2022
Sell 81.3 K USD
Spurr Robert
U.S. President-Pharma Business
- 3251
25.02 USD
3 years ago
Jan 18, 2022
Sell 86.6 K USD
Spurr Robert
U.S. President-Pharma Business
- 3251
26.63 USD
3 years ago
Nov 30, 2021
Bought 1.21 M USD
Miller Steven D
Director
+ 50000
24.2365 USD
3 years ago
Nov 30, 2021
Bought 242 K USD
Miller Steven D
Director
+ 10000
24.1699 USD
3 years ago
Aug 05, 2021
Bought 36.3 K USD
VON ESCHENBACH ANDREW C.
Director
+ 1400
25.94 USD
3 years ago
Aug 04, 2021
Bought 250 K USD
DE SCHUTTER RICHARD U
Director
+ 10000
25.0123 USD
3 years ago
Jun 11, 2021
Sell 539 K USD
Eldessouky Sam
EVP & Chief Financial Officer
- 17000
31.6815 USD
3 years ago
Jun 02, 2021
Sell 3.86 M USD
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
- 121198
31.83 USD
3 years ago
May 26, 2021
Sell 351 K USD
WECHSLER AMY B
Director
- 11037
31.785 USD
4 years ago
Nov 23, 2020
Sell 29.1 K USD
Humphries William D.
President, Ortho-Dermatologics
- 1483
19.6328 USD
4 years ago
Nov 24, 2020
Sell 425 K USD
Humphries William D.
President, Ortho-Dermatologics
- 21658
19.6323 USD
4 years ago
Nov 27, 2020
Sell 268 K USD
Humphries William D.
President, Ortho-Dermatologics
- 13663
19.6302 USD
4 years ago
Sep 08, 2020
Sell 91.6 K USD
Humphries William D.
President, Ortho-Dermatologics
- 5667
16.17 USD
4 years ago
Jun 05, 2020
Bought 18.2 M USD
ValueAct Holdings, L.P.
Director
+ 948353
19.24 USD
4 years ago
Jun 05, 2020
Sell 18.2 M USD
ValueAct Holdings, L.P.
Director
- 948353
19.24 USD
4 years ago
May 14, 2020
Bought 9.31 M USD
Paulson John
+ 585100
15.92 USD
4 years ago
May 14, 2020
Bought 9.92 M USD
Paulson John
+ 624900
15.87 USD
4 years ago
May 14, 2020
Bought 1.1 M USD
Paulson John
+ 70000
15.65 USD
4 years ago
May 14, 2020
Bought 5.53 M USD
Paulson John
+ 348920
15.85 USD
4 years ago
May 13, 2020
Bought 10.8 M USD
Paulson John
+ 645844
16.7 USD
4 years ago
May 13, 2020
Bought 1.33 M USD
Paulson John
+ 80300
16.58 USD
4 years ago
May 13, 2020
Bought 9.86 M USD
Paulson John
+ 603900
16.32 USD
4 years ago
May 12, 2020
Bought 13.8 M USD
Paulson John
+ 799900
17.24 USD
4 years ago
May 12, 2020
Bought 11.9 M USD
Paulson John
+ 678400
17.47 USD
4 years ago
May 12, 2020
Bought 6.5 M USD
Paulson John
+ 374836
17.33 USD
4 years ago
May 12, 2020
Bought 2.85 M USD
Paulson John
+ 162900
17.5 USD
4 years ago
May 12, 2020
Bought 432 K USD
Paulson John
+ 25000
17.3 USD
4 years ago
Mar 12, 2020
Bought 38.8 K USD
Ross Thomas W. Sr.
Director
+ 2500
15.535 USD
4 years ago
Mar 10, 2020
Bought 80.1 K USD
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
+ 4390
18.2473 USD
4 years ago
Mar 10, 2020
Bought 20 K USD
VON ESCHENBACH ANDREW C.
Director
+ 1100
18.1785 USD
5 years ago
Mar 03, 2020
Bought 115 K USD
DE SCHUTTER RICHARD U
Director
+ 5000
23.083 USD
4 years ago
Mar 10, 2020
Bought 69.4 K USD
DE SCHUTTER RICHARD U
Director
+ 3800
18.2572 USD
5 years ago
Sep 13, 2019
Bought 699 K USD
PAPA JOSEPH C
CHAIRMAN & CEO
+ 30000
23.31 USD
5 years ago
Aug 19, 2019
Sell 235 K USD
McKenna Mark C.
President, Salix
- 10773
21.8343 USD
5 years ago
Aug 16, 2019
Bought 650 K USD
Humphries William D.
President, Ortho-Dermatologics
+ 30703
21.1752 USD
5 years ago
Aug 12, 2019
Sell 76.7 K USD
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
- 3418
22.4475 USD
5 years ago
Jul 11, 2019
Sell 98.4 K USD
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
- 3968
24.81 USD
6 years ago
Feb 28, 2019
Bought 710 K USD
PAPA JOSEPH C
CHAIRMAN & CEO
+ 30000
23.67 USD
6 years ago
Dec 14, 2018
Bought 584 K USD
APPIO THOMAS
Pres&Co-Head Bausch&Lomb/Int'l
+ 25440
22.9567 USD
6 years ago
Oct 15, 2018
Sell 382 K USD
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
- 15404
24.83 USD
6 years ago
Oct 16, 2018
Sell 116 K USD
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
- 4542
25.5 USD
6 years ago
Sep 13, 2018
Bought 3 M USD
DE SCHUTTER RICHARD U
Director
+ 125000
23.96 USD
6 years ago
Sep 14, 2018
Bought 226 K USD
Herendeen Paul
EVP and CFO
+ 10000
22.61 USD
6 years ago
Sep 14, 2018
Bought 670 K USD
PAPA JOSEPH C
CHAIRMAN & CEO
+ 30000
22.32 USD
6 years ago
May 15, 2018
Bought 218 K USD
DE SCHUTTER RICHARD U
Director
+ 10000
21.8 USD
6 years ago
May 15, 2018
Bought 327 K USD
DE SCHUTTER RICHARD U
Director
+ 15000
21.83 USD
6 years ago
Mar 13, 2018
Bought 241 K USD
Herendeen Paul
EVP and CFO
+ 15000
16.098 USD
6 years ago
Mar 13, 2018
Bought 482 K USD
PAPA JOSEPH C
CHAIRMAN & CEO
+ 30000
16.05 USD
6 years ago
Mar 08, 2018
Bought 153 K USD
DE SCHUTTER RICHARD U
Director
+ 10000
15.34 USD
7 years ago
Mar 06, 2018
Bought 109 M USD
Paulson John
Director
+ 7066629
15.4 USD
7 years ago
Mar 06, 2018
Sell 109 M USD
Paulson John
Director
- 7066629
15.4 USD
7 years ago
Nov 17, 2017
Bought 143 K USD
DE SCHUTTER RICHARD U
Director
+ 10000
14.33 USD
7 years ago
Nov 16, 2017
Bought 4.96 M USD
Paulson John
Director
+ 344216
14.3965 USD
7 years ago
Nov 16, 2017
Sell 4.95 M USD
Paulson John
Director
- 344216
14.3887 USD
7 years ago
Aug 21, 2017
Bought 70.3 K USD
DE SCHUTTER RICHARD U
Director
+ 4900
14.35 USD
7 years ago
Aug 21, 2017
Bought 73 K USD
DE SCHUTTER RICHARD U
Director
+ 5100
14.31 USD
7 years ago
May 11, 2017
Bought 278 K USD
DE SCHUTTER RICHARD U
Director
+ 20000
13.9 USD
7 years ago
Mar 15, 2017
Bought 108 K USD
DE SCHUTTER RICHARD U
Director
+ 10000
10.8 USD
7 years ago
Mar 14, 2017
Bought 257 K USD
Herendeen Paul
EVP and CFO
+ 24000
10.72 USD
8 years ago
Dec 14, 2016
Bought 73.6 K USD
Ross Thomas W. Sr.
Director
+ 5000
14.73 USD
8 years ago
Dec 12, 2016
Sell 51.6 M USD
Pershing Square Capital Management, L.P.
Director
- 3476690
14.85 USD
8 years ago
Dec 12, 2016
Bought 1.5 B USD
Pershing Square Capital Management, L.P.
Director
+ 9120000
165 USD
8 years ago
Aug 11, 2016
Bought 98.6 K USD
KARABELAS ARGERIS N
Director
+ 4000
24.65 USD
8 years ago
Jun 13, 2016
Bought 97.6 K USD
Ross Thomas W. Sr.
Director
+ 4000
24.4 USD
8 years ago
Jun 09, 2016
Sell 547 M USD
Pershing Square Capital Management, L.P.
Director
- 9120000
60 USD
8 years ago
Jun 09, 2016
Bought 5.47 M USD
Pershing Square Capital Management, L.P.
Director
+ 91200
60 USD
8 years ago
Jun 09, 2016
Sell 866 M USD
Pershing Square Capital Management, L.P.
Director
- 9120000
95 USD
8 years ago
Jun 09, 2016
Bought 547 M USD
Pershing Square Capital Management, L.P.
Director
+ 9120000
60 USD
8 years ago
Jun 10, 2016
Bought 4.94 M USD
PAPA JOSEPH C
CHAIRMAN & CEO
+ 202000
24.48 USD
9 years ago
Nov 05, 2015
Sell 11 M USD
Pearson J. Michael
Chief Executive Officer
- 147054
74.67 USD
9 years ago
Nov 05, 2015
Sell 61.4 M USD
Pearson J. Michael
Chief Executive Officer
- 800345
76.66 USD
9 years ago
Nov 05, 2015
Sell 29.5 M USD
Pearson J. Michael
Chief Executive Officer
- 350000
84.26 USD
9 years ago
Oct 21, 2015
Bought 79.4 K USD
Farmer Ronald Harold
Director
+ 500
158.79 USD
9 years ago
Oct 21, 2015
Bought 193 K USD
Farmer Ronald Harold
Director
+ 1000
193 USD
9 years ago
Aug 26, 2015
Bought 110 K USD
Farmer Ronald Harold
Director
+ 500
220 USD
9 years ago
Aug 21, 2015
Bought 157 K USD
Farmer Ronald Harold
Director
+ 700
224.97 USD
9 years ago
Aug 21, 2015
Bought 67.5 K USD
Farmer Ronald Harold
Director
+ 300
224.98 USD
9 years ago
Jul 31, 2015
Bought 181 K USD
Rosiello Robert L.
EVP, Chief Financial Officer
+ 704
257.25 USD
9 years ago
Jul 30, 2015
Bought 1.82 M USD
Rosiello Robert L.
EVP, Chief Financial Officer
+ 7171
253.99 USD
9 years ago
Jun 12, 2015
Bought 3 M USD
Rosiello Robert L.
Executive Vice President
+ 12900
232.51 USD
9 years ago
Jun 10, 2015
Sell 96.4 M USD
UBBEN JEFFREY W
Director
- 417919
230.6 USD
9 years ago
Jun 10, 2015
Sell 764 M USD
UBBEN JEFFREY W
Director
- 3488933
219 USD
9 years ago
Jun 10, 2015
Sell 7.23 M USD
UBBEN JEFFREY W
Director
- 31358
230.6 USD
9 years ago
Jun 10, 2015
Sell 57.3 M USD
UBBEN JEFFREY W
Director
- 261790
219 USD
9 years ago
Jun 08, 2015
Bought 145 K USD
Farmer Ronald Harold
Director
+ 500
289.2 USD
9 years ago
Jun 09, 2015
Bought 116 K USD
Farmer Ronald Harold
Director
+ 500
232.05 USD
9 years ago
Jun 01, 2015
Sell 24 K USD
Mirovsky Pavel
EVP, Pres. & GM Valeant EMENA
- 100
240 USD
9 years ago
Jun 02, 2015
Sell 3.55 M USD
Mirovsky Pavel
EVP, Pres. & GM Valeant EMENA
- 14900
237.94 USD
9 years ago
Jun 02, 2015
Sell 5.48 M USD
Mirovsky Pavel
EVP, Pres. & GM Valeant EMENA
- 23000
238.044 USD
9 years ago
May 26, 2015
Bought 585 K USD
Whitaker Anne Clem
Director
+ 2500
234 USD
9 years ago
May 26, 2015
Bought 1.18 M USD
Whitaker Anne Clem
Director
+ 5000
235 USD
9 years ago
May 04, 2015
Sell 20.2 M USD
Chai-Onn Robert Roswell
EVP, CLO, General Counsel
- 90938
222.5411 USD
10 years ago
Mar 02, 2015
Sell 18.2 M USD
Chai-Onn Robert Roswell
EVP, CLO, General Counsel
- 90939
200.0142 USD
10 years ago
Dec 12, 2014
Bought 80.2 K USD
Farmer Ronald Harold
Director
+ 500
160.48 USD
10 years ago
Dec 10, 2014
Bought 6.96 M USD
UBBEN JEFFREY W
Director
+ 50000
139.29 USD
10 years ago
Dec 09, 2014
Bought 28 M USD
UBBEN JEFFREY W
Director
+ 200000
140.25 USD
10 years ago
Dec 03, 2014
Bought 219 K USD
STEVENSON KATHARINE BERGHUIS
Director
+ 1500
145.73 USD
10 years ago
Nov 24, 2014
Bought 164 K USD
Farmer Ronald Harold
Director
+ 1000
163.95 USD
10 years ago
Nov 24, 2014
Bought 29.9 M USD
UBBEN JEFFREY W
Director
+ 210000
142.25 USD
7. News
Bausch Health Q4 Earnings Recap (Reiterating Buy Rating) Bausch Health reported strong Q4 results with a 6.2% Y/Y revenue increase and positive net income, driving a 10% stock rally. Key growth drivers include Salix, Xifaxan, and Solta, with a focus on long-term growth and debt management, peaking in 2028. Positive catalysts include FDA litigation outcomes and strategic decisions around Bausch & Lomb, enhancing shareholder value and future revenue potential. seekingalpha.com - 1 week ago
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive. zacks.com - 1 week ago
Compared to Estimates, Bausch (BHC) Q4 Earnings: A Look at Key Metrics Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 week ago
Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript Bausch Health Companies Inc. (NYSE:BHC ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Les Sulewski - Truist Securities Doug Miehm - RBC Capital Michael Freeman - Raymond James Michael Nedelcovych - TD Cowen Glen Santangelo - Jefferies Operator Greetings. Welcome to the Bausch Health Fourth Quarter 2024 Earnings Call. seekingalpha.com - 1 week ago
Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates Bausch Health (BHC) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.15 per share a year ago. zacks.com - 1 week ago
Bausch Health Announces Fourth Quarter and Full-Year 2024 Results Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidance Fourth Quarter Consolidated Revenues of $2.56 billion, up 6% on a Reported basis and up 9% on an Organic (non-GAAP)1 basis over the prior year period Full-Year Consolidated Revenues of $9.63 billion, up 10% on a Reported basis and 8% on an Organic (non-GAAP)1 basis, with growth in all segments GAAP Net Income Attributable to Bausch Health Companies Inc. of $93 million for the quarter and GAAP Net Loss of $46 million for the year Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $935 million for the quarter, up 8%, and $3.31 billion for the year, up 10% LAVAL, QC / ACCESS Newswire / February 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth quarter and full-year 2024 financial results and other key updates for the quarter. "2024 was a year of delivering on our commitments, where we achieved the high-end of our revenue guidance range, and exceeded our adjusted EBITDA excluding Bausch + Lomb, and adjusted operating cash flow guidance expectations. accessnewswire.com - 1 week ago
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2024 financial results. “Underpinning our recent success is a commitment to long-term, profitable growth,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for pati. businesswire.com - 1 week ago
What Analyst Projections for Key Metrics Reveal About Bausch (BHC) Q4 Earnings Beyond analysts' top -and-bottom-line estimates for Bausch (BHC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. zacks.com - 2 weeks ago
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida on February 24. accessnewswire.com - 2 weeks ago
Earnings Preview: Bausch Health (BHC) Q4 Earnings Expected to Decline Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
Skincare Devices Market and Competition Analysis 2025-2030, Featuring 42 Major Companies Including Alma Lasers, Bausch Health Companies, Lumenis, Merz Pharma & More Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth globenewswire.com - 2 weeks ago
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the opening of the 2025 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals. accessnewswire.com - 3 weeks ago
8. Profile Summary

Bausch Health Companies Inc. BHC

image
COUNTRY CA
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 2.69 B
Dividend Yield 0.00%
Description Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Contact 2150 St. ElzEar Boulevard West, Laval, QC, H7L 4A8 https://www.bauschhealth.com
IPO Date March 29, 1994
Employees 20270
Officers Mr. Jean-Jacques Charhon Executive Vice President & Chief Financial Officer Ms. Jiny Kim M.B.A. Senior Vice President of Solta Medical Ms. Aimee J. Lenar Executive Vice President of US Pharma Mr. Mirza Dautbegovic Executive Vice President & Chief Operating Officer Ms. Kathleen Fitzpatrick Executive Vice President and Chief HR & Communications Officer Ms. Seana Carson Executive Vice President & General Counsel Mr. Garen Sarafian Vice President & Head of Investor Relations Mr. Cees Heiman Senior Vice President of Europe & Canada Mr. Thomas J. Appio Chief Executive Officer & Director Mr. Donald Pearl Senior Vice President of Ortho Dermatologics